Probiotic CFU Stability and Strain Identity: Defending the Label Claim at End of Shelf Life

A probiotic labelled simply 'Lactobacillus acidophilus' is making an under-specified claim — clinical and safety data are tied to specific strains, not species, and FDA, EFSA and Health Canada increasingly expect strain-level identification. Strain identification has moved from 16S rRNA sequencing (genus and species level only) and pulsed-field gel electrophoresis through MALDI-TOF mass spectrometry to whole-genome sequencing (WGS), now the consensus reference standard. WGS provides definitive strain matching against a deposited reference sequence (typically lodged with a culture collection such as ATCC, DSMZ, NCIMB or LMG), confirms the absence of antimicrobial resistance gene transfer risk per EFSA guidance, and is required for QPS (Qualified Presumption of Safety) listing in the EU. Every probiotic specification should reference the deposit number of the strain (e.g. ATCC PTA-XXXXX), require WGS-verified identity on each incoming lot from the strain supplier, and link the strain to its documented safety and efficacy evidence base.

Colony-Forming Unit enumeration is performed by serial dilution and plating on strain-appropriate selective or differential agar, with incubation at the strain-optimal temperature and atmosphere, followed by colony counting. The pharmacopoeial reference is USP <2055> Microbial Examination of Nonsterile Products: Recommended Acceptance Criteria for Pharmaceutical Preparations and USP General Chapter <61> and <62>, with strain-specific media recommendations from compendia and the supplier. Common sources of inter-laboratory disagreement: media formulation differences (MRS variants), incubation atmosphere (strict anaerobic vs CO2-enriched vs ambient), incubation temperature (37 °C vs 30 °C), incubation duration (48 h vs 72 h), and recovery from challenging matrices (gummies, lozenges, oils). Flow cytometry with viability staining (ISO 19344) is increasingly used as a faster, more reproducible alternative and is accepted by IPA (International Probiotics Association) for active fluorescent unit (AFU) reporting; flow cytometry generally returns higher counts than plate counts because it detects viable-but-non-culturable cells. The label method should be specified — switching methods mid-lifecycle without bridging studies is a frequent finding source.

Because probiotic cells die off across shelf life, the manufacturing target CFU is set above the label claim to ensure the end-of-shelf-life count still meets label. The overage is calculated from stability data: rate of die-off in the finished product matrix and packaging at the labelled storage condition, target shelf life, and the desired confidence margin. Typical overages range from 30% to over 300% depending on strain robustness, matrix hostility (gummies and chewables are hostile, capsules with desiccants are friendly), water activity, packaging moisture barrier, and storage condition (refrigerated vs ambient). The overage must be set in the master manufacturing record, monitored across stability, and re-evaluated annually against accumulated stability data. Over-overage drives unnecessary cost and can push above the upper specification limit at release; under-overage leads to end-of-shelf-life failures and re-labelling or recall.

Water activity (aw) is the dominant driver of probiotic die-off rate at ambient storage. Strains in dry capsule or sachet form at aw < 0.25 typically retain CFU within label across 24 months at room temperature; at aw 0.3-0.4 the die-off rate accelerates sharply; above aw 0.5 most strains lose viability rapidly. Packaging controls: high moisture-barrier laminates (aluminium or high-barrier plastic), integrated desiccants, nitrogen flush of headspace, and storage condition labelling (refrigeration significantly extends shelf life for less robust strains). Matrix-specific complications: gummies sit at aw 0.5-0.7 and are typically incompatible with conventional probiotics — products in this format require either strain-specific spore-formers (e.g. Bacillus coagulans, Bacillus subtilis), encapsulation technology, or sharply reduced label claims and shelf lives. Liquid probiotics require refrigeration plus careful matrix design and frequent stability monitoring.

Probiotic stability follows the ICH Q1A(R2) climatic-zone framework (long-term study at the labelled storage condition, accelerated study at elevated temperature and humidity, intermediate study for borderline products) but with a critical twist: the controlling specification is the end-of-shelf-life CFU count against label claim, not just release. Test points typically at 0, 3, 6, 9, 12, 18, 24, 36 months at long-term condition, with strain-specific accelerated condition modelling. Q1E extrapolation is limited for biological products — accelerated data alone is rarely sufficient to support an extended shelf life claim and long-term data is the gold standard. The stability protocol must specify the enumeration method (consistent across the study), the acceptance criterion (label claim with stated confidence interval), and the action plan for trending toward the limit. Stability commitments cover ongoing primary stability batches, annual stability batches, and stability re-evaluation triggered by formulation, packaging or supplier change.